Patents
Literature
38 results about "Stem cell homing" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In stem cell science, the word "homing" describes stem cells' ability to find their destination, or "niche.". Identification of specific cues that steer stem cells to their niche and increase the efficiency of the homing process is an area of intense investigation. The effort has several parts: making...
Hydrogel bioscaffoldings and biomedical device coatings
Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-l-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-l-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine / DNA plasmid complex, or a DNA / polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
Owner:ABBOTT CARDIOVASCULAR
Bispecific antibodies and agents to enhance stem cell homing
InactiveUS20080057053A1Enhance cell engraftmentConducive to survivalIn-vivo radioactive preparationsPeptide/protein ingredientsAntigenStem cell homing
A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and / or agents to enhance cell therapy.
Owner:CARDIAC PACEMAKERS INC
Hydrogel bioscaffoldings and biomedical device coatings
Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine / DNA plasmid complex, or a DNA / polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
Owner:ABBOTT CARDIOVASCULAR
Hydrogel bioscaffoldings and biomedical device coatings
Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-l-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-l-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine / DNA plasmid complex, or a DNA / polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
Owner:ABBOTT CARDIOVASCULAR
Methods of Improving Stem Cell Homing and Engraftment
ActiveUS20100061963A1Promote migrationEnhancing stem cell mobilizationBiocideCulture processStem cell homingNicotinamide
A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.
Owner:GAMIDA CELL
CCR ligands for stem cell homing
InactiveUS20060182712A1Improve concentrationIncrease the number ofBiocidePeptide/protein ingredientsStem cell homingPhysiology
Owner:THE CLEVELAND CLINIC FOUND
Hydrogel bioscaffoldings and biomedical device coatings
Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine / DNA plasmid complex, or a DNA / polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
Owner:ABBOTT CARDIOVASCULAR
Methods and devices to regulate stem cell homing
InactiveUS20080057027A1Increased expression and activationIncrease expression and activationBiocidePeptide/protein ingredientsStem cell homingBiological activation
Owner:CARDIAC PACEMAKERS INC
Methods of improving stem cell homing and engraftment
ActiveUS8846393B2Improving stem cell engraftment and/or homingBiocideCulture processStem cell homingNicotinamide
A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.
Owner:GAMIDA CELL
Methods for enhancing stem cell engraftment during transplantation
InactiveUS20080085264A1Improving stem cell transplant efficiencyEasy to returnBiocideGenetic material ingredientsStem cell homingHematopoietic stem cell transplantation
The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.
Owner:CHRISTOPHERSON II KENT W +2
CCR ligands for stem cell homing
Owner:THE CLEVELAND CLINIC FOUND
Fast stem cell homing method
InactiveCN103055418ANo side effectsEfficient and quick homingElectrotherapyMagnetotherapyStem cell homingMagnetic bead
The invention provides a method which enables stem cells to be homed quickly and effectively. The stem cell homing method includes the steps that immunomagnetic beads are used for marking the stem cells, and the particle size of each immunomagnetic bead is 40-60 nanometers; the marked stem cells are injected into a circulatory system of specific tissue; and a positive magnetic pole and a negative magnetic pole point to body surface portions corresponding to the specific tissue, and in the circulation process of the circulatory system, the stem cells are homed into the specific tissue quickly and accurately, wherein the magnetic field strength between the positive magnetic pole and the negative magnetic pole is 8,400-18,600 gausses. According to the stem cell homing method, the magnetic characteristic of the superparamagnetism magnetic beads is utilized innovatively, the magnetic attraction technology is adopted to enable the stem cells to be homed into the specific tissue, the stem cells can be helped to differentiate into functional adult cells in the specific tissue, and a new direction is exploited for clinical application of the stem cells.
Owner:北京清美联创干细胞科技有限公司
Adipose-derived stem cell transfected by magnetic nanoparticle mediated IGF-I gene and preparation method thereof
InactiveCN104630269AImprove targetingHigh transfection efficiencyVector-based foreign material introductionForeign genetic material cellsMagnetite NanoparticlesIn vivo
The invention relates to the field of articular cartilage injury repair and particularly relates to an adipose-derived stem cell transfected by a magnetic nanoparticle mediated IGF-I gene and a preparation method thereof. The method comprises three steps of ADSCs separation and culture, Fe3O4 MNPs preparation and in vitro transfection. The mediated IGF-I gene with an iron oxide magnetic nanoparticle as a vector is used for transfecting ADSCs to achieve over expression of IGF-I, and the homing rate of stem cells is improved by a dynamically rotating magnetic field in vitro in a targeting manner, and the iron oxide magnetic nanoparticle used in the research is a non-virus gene vector, has the advantages of being safe, harmless, high targeting and efficient and stable expression of a target gene, and the like, can be used for greatly improving the gene transfection efficiency, and more importantly can be used for solving the problem of low homing rate of ADSCs in a scaffold in an implant via the dynamically rotating magnetic field in vitro, and positioning and tracking the stem cell in vivo through magnetic resonance technology.
Owner:HANGZHOU CITY XIAOSHAN DISTRICT TRADITIONAL CHINESE MEDICAL HOSPITAL
Targeted antibiosis and in-situ osteogenesis promoting bifunctional material as well as preparation method and application thereof
ActiveCN112220967APromote regenerationImprove antibacterial propertiesPharmaceutical delivery mechanismTissue regenerationAnti bacterialStem cell homing
The invention provides a targeted antibiosis and in-situ osteogenesis promoting bifunctional material as well as a preparation method and application thereof, and belongs to the technical field of periodontal tissue repair and regeneration. The bifunctional material comprises a gel scaffold and SDF-1, wherein the gel scaffold is formed by cross-linking PEG-DA and Peptide, has a temperature-sensitive characteristic and can respond to gingipains, and the SDF-1 is further loaded by the material and has a recruited stem cell homing function. By developing and preparing the gingipain response typetemperature-sensitive gel material, long-acting targeted antibiosis and in-situ regeneration promotion of a periodontal defect part can be realized simultaneously along with release of short antibacterial peptide and the SDF-1. Tests prove that the PEG-DA-Peptide@SDF-1 bifunctional material prepared by the invention is temperature-sensitive and can be applied by injection, and has good long-actingtargeted antibiosis and in-situ regeneration promoting effects, so that the bifunctional material has good practical application value.
Owner:SHANDONG UNIV
Channel ushering drug common achyranthes-containing traditional Chinese drug composition for improving bone marrow stem cell homing
InactiveCN102423351AHoming promotionPromote new lifeAnthropod material medical ingredientsSkeletal disorderDiseaseSide effect
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Methods for Enhancing Stem Cell Engraftment During Transplantation
InactiveUS20110091429A1Improve transplanting efficiencyEasy to returnBiocideMicrobiological testing/measurementStem cell homingHematopoietic stem cell transplantation
The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.
Owner:CHRISTOPHERSON II KENT W +2
Method for screening stem cell homing promotion drugs, recombinant vector and cell strain
InactiveCN109136263AMicrobiological testing/measurementGenetically modified cellsCXCR4Stem cell homing
The invention relates to the technical field of biology, in particular to a recombinant vector and a stable cell strain containing the recombinant vector. The recombinant vector and the stable cell strain containing the recombinant vector can be used for screening stem cell homing promotion drugs. The recombinant vector contains a CXCR4 promoter sequence and a luc2 luciferase report gene; and theluc2 luciferase report gene is positioned at the downstream of the CXCR4 promoter sequence. The stable cell strain which contains the recombinant vector and an internal reference luciferase vector canbe used for detecting the expression activity level of the CXCR4 gene, and then are used for screening the stem cell homing promotion drugs at high throughput. Therefore, the stable cell strain is added in a candidate drug for stimulation, through luc2 relative fluorescence intensity, the activity of promotion of the candidate drug on expression of the CXCR4 promoter can be evaluated, therefore,the stem cell homing drugs or drugs for treating myocardial infarction or assisting in treatment of the myocardial infarction are screened, and the application prospect is wide.
Owner:SHANGHAI UNIV OF T C M
Fusion polypeptide, application of fusion polypeptide in enhancement of stem cell homing ability and anti-apoptotic ability and pharmaceutical composition
PendingCN110804100ASmall molecular weightEasy to synthesizePeptide/protein ingredientsAntibody mimetics/scaffoldsCXCR4Stem cell homing
The invention relates to the field of medicine, and in particular relates to a fusion polypeptide, an application of the fusion polypeptide in enhancement of stem cell homing ability and anti-apoptotic ability and a pharmaceutical composition. The fusion polypeptide includes an SDF-1 derived peptide, an optional linker sequence and an RGD peptide having an RGD sequence in sequence from the 5' endto the 3' end, wherein the linker sequence is used to link the SDF-1 derived peptide and the RGD peptide, the SDF-1 derived peptide can specifically bind to CXCR4 and / or CXCR7 receptors expressed by stem cells, and the RGD peptide can specifically bind to an integrin receptor. The fusion polypeptide has the advantages of low costs and a long half-life period, and can enhance the homing ability andanti-apoptotic ability of the stem cells.
Owner:中国人民解放军陆军特色医学中心
Bispecific antibodies and agents to enhance stem cell homing
InactiveUS8372399B2Enhances and activates adhesion molecule expressionEnhancing engraftmentIn-vivo radioactive preparationsPeptide/protein ingredientsAntigenStem cell homing
A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and / or agents to enhance cell therapy.
Owner:CARDIAC PACEMAKERS INC
Double-layer hydrogel stent capable of releasing medicine in time sequence as well as preparation method and application of double-layer hydrogel stent
The invention discloses a double-layer hydrogel stent capable of releasing medicine in time sequence as well as a preparation method and application of the double-layer hydrogel stent. The scaffold comprises an inner hydrogel and an outer hydrogel coating the inner hydrogel, the outer hydrogel is loaded with cell factors, and the cell factors have the following effects of collecting neutrophils and promoting polarization of the neutrophils into subtypes with stem cell collection; the inner layer hydrogel is loaded with neurotrophic factors. According to the hydrogel scaffold, ordered slow release of cell factors (such as IL-8) and neurotrophic factors (such as NGF) is achieved through the structural design of the inner hydrogel layer and the outer hydrogel layer, neutrophils and sensory nerves can be activated in sequence in a bone defect area, the neutrophils are collected in the defect area, stem cell homing is promoted, and osteogenesis is started; then, local sensory nerves are induced to grow in through the lagged and continuously released NGF, the sensory nerves are stimulated to play an immune regulation role, inflammation dissipation is promoted, and finally repair and regeneration of refractory bone defects are promoted.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators
InactiveUS20080112933A1Increasing stem cell mobilizationEnhance mobilizationBiocideGenetic material ingredientsStem cell homingBiology
Owner:THE GENERAL HOSPITAL CORP
Bioactive scaffold for repairing endometrium and improving fertility
ActiveCN110898254ARepair the inner membrane structureImprove fertilityProsthesisBiotechnologyBiocompatibility
The invention relates to a bioactive scaffold for repairing endometrium and improving fertility. The scaffold comprises a substrate and bioactive factors contained by the substrate. Endogenous stem cells are recruited and captured by bioactive factors. The stem cells have pluripotency and play a role in immune regulation and control on a wound surface, thereby effectively promoting endometrial repairing and remarkably increasing the fertility rate. According to the invention, the endogenous stem cell homing means integrated with collection and capturing is employed to repair the damaged endometrium so as to solve problems of intrauterine adhesion, reduced fertility rate and the like caused by a hysteroscope operation, thereby eliminating the potential safety hazards caused by usage of exogenous cells in the traditional repair material. The adopted raw materials have high biocompatibility; the preparation process is simple; exogenous cells are not contained; and the biological safety ishigh.
Owner:ZHEJIANG UNIV
Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
The present invention discloses a method of treating the infarcted myocardial tissue, including the concentration of SDF-1 protein in the infarcted tissue. The concentration of stem cells in the peripheral blood of the infarcted tissue is also increased. When the concentration of SDF-1 protein in the infarcted tissue is increased, the number of stem cells in the peripheral blood is also increased at the same time.
Owner:THE CLEVELAND CLINIC FOUND
Methods and devices to regulate stem cell homing
InactiveUS8636995B2Increased expression and activationIncrease expression and activationBiocidePeptide/protein ingredientsStem cell homingBiological activation
Owner:CARDIAC PACEMAKERS INC
Medical implant
ActiveUS20180214613A1Promote tissue formationPromote regeneration of articularPeptide/protein ingredientsJoint implantsSkeletal tissueCell free
The present invention relates to a cell-free, multi-layered medical device having bespoke, multifunctional bioactivity for the purpose of regeneration of skeletal tissues. The medical device may actively promote homing of stem cells into the medical device and promote their differentiation into the required cell type and promote de-novo tissue formation. The invention includes methods of making the medical device, uses of the medical device in promoting regeneration of the articular cartilage of a joint surface and in promoting healing and regeneration of skeletal tissues, for example, meniscal cartilage, tendon and ligament tissues and also healing of bone tissue indications such as fractures.
Owner:UNIV OF SHEFFIELD
A dual-functional material targeting antibacterial and in situ promoting bone formation and its preparation method and application
ActiveCN112220967BPromote regenerationImprove antibacterial propertiesPharmaceutical delivery mechanismDepsipeptidesStem cell homingAntimicrobial peptides
The invention provides a dual-functional material targeting antibacterial and in situ osteogenesis, a preparation method and application thereof, and belongs to the technical field of periodontal tissue repair and regeneration. The bifunctional material includes a thermosensitive gel scaffold formed by cross-linking PEG-DA and Peptide and capable of responding to gingivalin, and SDF-1, which is further loaded with the material, has the function of recruiting stem cells and homing. The developed and prepared gingivalin-responsive thermosensitive gel material can simultaneously achieve long-term targeted antibacterial and in situ regeneration promotion of periodontal defects along with the release of short antimicrobial peptides and SDF‑1. Tests have proved that the PEG-DA-Peptide@SDF-1 bifunctional material prepared by the present invention is injectable and has good long-term targeted antibacterial and in-situ regeneration promotion effects, so it has good practical application value.
Owner:SHANDONG UNIV
Bone-blood vessel coupling regeneration material based on S1P modified decellularized fish scale bone meal as well as preparation method and application of bone-blood vessel coupling regeneration material
The invention discloses a bone-blood vessel coupling regeneration material based on S1P modified decellularized fish scale bone meal as well as a preparation method and application thereof, and belongs to the technical field of biology. After the fish scales are treated by a decellularization method, sphingosine-1-phosphoric acid (S1P) is efficiently anchored on the surfaces of the fish scales by utilizing a cationic gelatin middle layer, and a novel bone-blood vessel coupling regeneration material is developed. The bone-blood vessel coupling regeneration material retains natural components and topological structures of fish scales, and can guide ordered deposition of calcium and phosphorus to improve bone matrix density and compression strength; the endogenous bone marrow mesenchymal stem cells and vascular endothelial cells are actively collected to migrate to the center of a defect cavity by loading the S1P to simulate the homing principle of natural stem cells in an organism, osteogenesis and angiogenesis signal channels are synchronously activated, and endogenous bone-blood vessel coupling regeneration is rapidly started. The invention provides an effective strategy for regulating and controlling osteogenesis-angiogenesis coupling for the field of bone injury repair.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Dosage forms for local injection containing eltrombopag for use in treating degenerative diseases and improving stem cell homing - Patent Application 20070122999
PendingJP2025542310APowder deliveryOrganic active ingredientsImmunologic disordersAutoimmune condition
The present invention relates to a controlled-release pharmaceutical composition comprising at least a controlled-release pharmaceutical dosage form containing EPAG, the controlled-release pharmaceutical composition being suitable for local injection into an affected area. The present invention also relates to a controlled-release pharmaceutical composition in powder form for preparing the pharmaceutical composition suitable for local injection, and a kit for preparing the pharmaceutical composition comprising an aqueous injection vehicle and a controlled-release dosage form or a mixture of controlled and immediate-release dosage forms containing EPAG, the pharmaceutical composition optionally including an excipient. The composition is useful for local injection in patients to improve stem cell homing and / or treat non-malignant hematological disorders, malignant hematological diseases, primary immunodeficiencies, autoimmune diseases, inborn errors of metabolism, and / or degenerative diseases / injuries.
Owner:PK MED SAS
Medical implant
ActiveUS10765779B2Promote stem cell homing into the implantEncourage differentiation in situPeptide/protein ingredientsJoint implantsArticular surfacesSkeletal tissue
The present invention relates to a cell-free, multi-layered medical device having bespoke, multifunctional bioactivity for the purpose of regeneration of skeletal tissues. The medical device may actively promote homing of stem cells into the medical device and promote their differentiation into the required cell type and promote de-novo tissue formation. The invention includes methods of making the medical device, uses of the medical device in promoting regeneration of the articular cartilage of a joint surface and in promoting healing and regeneration of skeletal tissues, for example, meniscal cartilage, tendon and ligament tissues and also healing of bone tissue indications such as fractures.
Owner:UNIV OF SHEFFIELD
Mediterranean anemia treatment method based on stem cell technology and application
PendingCN121102498APeptide/protein ingredientsPharmaceutical non-active ingredientsAptamerCell adhesion
The invention discloses a thalassemia treatment method based on a stem cell technology and application. The thalassemia treatment method comprises the following steps: collecting a peripheral blood sample of a patient, and carrying out stem cell isolated culture; constructing a nucleic acid aptamer by combining a vascular cell adhesion molecule-1 and a stromal cell-derived factor-1 in a bone marrow microenvironment; connecting a nucleic acid aptamer, a cell adhesion promoting peptide and a stem cell growth factor, and constructing a homing guiding reagent; preparing nano liposome and nano polymer particles; the nucleic acid aptamer is connected to the surfaces of the nano-liposome and the nano-polymer particles, and is grafted with a temperature-responsive material to obtain the nano-carrier with a responsive release function; stem cell growth factors and platelet-derived growth factors are mixed with gelatin microspheres to form a slow release system; the cultured stem cells are mixed with a homing guide reagent, a nano-carrier and a slow release system, and are transplanted into the body of a patient through intramedullary injection. The stem cell homing efficiency can be improved, and the treatment effect on thalassemia is improved.
Owner:ZHEJIANG UNIV